Duke Capital Partners portfolio company, xilis, has closed a $19M+ extension to its Series A financing
Duke Capital Partners portfolio company and Durham-based startup, xilis, has closed a $19M+ extension to its Series A financing, bringing the total amount raised to over $89M. xilis is a pioneering biotech company developing its MicroOrganoSphereTM (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development.
We are proud to build upon our partnership with xilis’ CEO, and former Duke University Pratt School of Engineering professor, Xiling Shen, Duke University Health System professor David Hsu, MD, Breakthrough Prize Foundation winner Hans Clevers, CFO Gary Yeung, CFA, and the xilis team. xilis is a spinout of Duke’s Office for Translation & Commercialization at Duke University.
In addition to Duke Capital Partners, existing investors participating in this fundraising round include GV (formerly Google Ventures), Mubadala, Two Sigma Ventures, Felicis Ventures, Pear VC, Catalio Capital Management, EQT Group, and Alix Ventures. New investors in this round include FPV Ventures, Alexandria Real Estate Equities, Inc., and other strategic partners.
The company will use the Series A funding to advance its proprietary MOS platform. This innovative MOS technology is the first truly scalable patient-derived model that recreates the tumor microenvironment and immune interactions necessary for next-generation immuno-oncology and cell therapy drug discovery.
Congratulations to the xilis team — we are proud to be your partner and we look forward to supporting your next breakthrough!